Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy

Current Topics in Medicinal Chemistry

Volumn 7, Issue 17, 2007, Pages 1660-1674

  Meurs, Alfred ^a,b   Clinckers, Ralph ^b   Ebinger, Guy ^a   Michotte, Yvette ^b   Smolders, Ilse ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Epilepsy; Ligands; Neuropeptide Y; NPY

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ANTICONVULSIVE AGENT; ANTISENSE OLIGONUCLEOTIDE; APREPITANT; ARGIPRESSIN; GR 231118; GW 438014A; INSULIN; LIPOSOME; MK 0557; MORPHINE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR AGONIST; NEUROPEPTIDE Y2 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y4 RECEPTOR AGONIST; NEUROPEPTIDE Y5 RECEPTOR AGONIST; NEUROPEPTIDE Y5 RECEPTOR ANTAGONIST; OLCEGEPANT; PARVOVIRUS VECTOR; PEPTIDE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANTICONVULSANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN DEPTH STIMULATION; BRAIN MAPPING; BRAIN REGION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; EPILEPSY; EPILEPTOGENESIS; GENE THERAPY; HUMAN; MAJOR DEPRESSION; MIGRAINE; MOLECULAR MIMICRY; NERVE INJURY; NEUROMODULATION; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; OBESITY; PAIN; PATIENT COMPLIANCE; POSTOPERATIVE VOMITING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SEIZURE; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; LIGANDS; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y;

EID: 36248966584     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607782340975     Document Type: Review

References (222)

1. Holden E.W.; Thanh Nguyen H.; Grossman E.; Robinson S.; Nelson L.S.; Guntér M.J.; Von Worley A.; Thurman D.J. Estimating prevalence, incidence, and disease-related mortality for patients with epilepsy in managed care organizations. Epilepsia 2005, 46, 311-319.
2. Hauptmann A. Luminal bei epilepsie. Munch. Med. Wochenschr. 1907.
3. Czapinski P.; Blaszczyk B.; Czuczwar SJ. Mechanisms of action of antjepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 3-14.
4. Lynch B.A.; Lambeng N.; Nocka K.; Kensel-Hammes P.; Bajjalieh S.M.; Matagne A.; Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA 2004, 101, 9861-9866.
5. Kwan P.; Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342, 314-319.
6. Kim W.J.; Park S.C.; Lee S.J.; Lee J.H.; Kim J.Y.; Lee B.I.; Kim D.I. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999, 40, 290-293.
7. Semah, F.; Picot M.C.; Adam C.; Broglin D.; Arzimanoglou A.; Bazin B.; Cavalcanti D.; Baulac M. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998, 51, 1256-1262.
8. Stephen L.J.; Kwan P.; Brodie M.J. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001, 42, 357-362.
9. Brodie M.J.; Dichter M.A. Antiepileptic drugs. N. Engl. J. Med. 1996, 334, 168-175.
10. Dichter M.A; Brodie M.J. New antiepileptic drugs. N. Engl. J. Med. 1996, 334, 1583-1590
11. Kwan P.; Brodie M.J. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001, 357, 216-222.
12. Pack A.M.; Gidal B.; Vazquez B. Bone disease associated with antiepileptic drugs. Cleve. Clin. J. Med. 2004, 71 Suppl 2, 42-48.
13. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005, 46 (Suppl 9), 117-124.
14. Penovich P.E. The effects of epilepsy and its treatment on sexual and reproductive function. Epilepsia 2000, 41 (Suppl 2), 53-61.
15. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003, 17, 781-791.
16. Temkin N.R. Antiepileptogenesis and seizure prevention trials with ahtiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001, 42, 515-524.
17. Beghi E. Overview of studies to prevent posttraumatic epilepiy. Epilepsia 2003, 44 Suppl 10, 21-26.
18. Vezzani A.; Hoyer D. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur. J. Neurosci. 1999, 11, 3767-3776.
19. Garant D.S.; Iadarola M.J.; Gale K. Substance P antagonists in substantia nigra are anticonvulsant. Brain Res. 1986, 382, 372-378.
20. Zachrisson Q,; Lindefors N.; Brene S. A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res. Mol. Brain Res. 1998, 60, 291-295.
21. Mazarati A.M. Galanin and galanin receptors in epilepsy. Neuropeptides 2004, 38, 331-343.
22. Ehlers C.L.; Henriksen S.J.; Wang M.; Rivier J.; Vale W.; Bloom F.E. Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res. 1983, 278, 332-336.
23. Tchekalarova J.; Georgiev V. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility? Life Sci. 2005, 76, 955-970.
24. Stragier B.; Clinckers R.; Meurs A.; De Bundel D.; Sarre S.; Ebinger G.; Michotte Y.; Smolders I. Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J. Neurochem. 2006, 98, 1100-1113.
25. Vezzani A.; Sperk G.; Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999, 22, 25-30.
26. Tatemoto K.; Carlquist M.; Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296, 659-660.
27. Larhammar D.; Soderberg C.; Lundell I. Evolution of the neuropeptide Y family and its receptors. Ann. N. Y. Acad. Sci. 1998, 839, 35-40.
28. Chronwall B.M.; DiMaggio D.A.; Massari V.J.; Pickel V.M.; Ruggiero D.A.; O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985, 15, 1159-1181.
29. de Quidt M.E.; Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system - I. Radioimmunoassay and chromatographic characterisation. Neuroscience 1986, 18, 527-543.
30. de Quidt M.E.; Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system - II. Immunohistochemical analysis. Neuroscience 1986, 18, 545-618.
31. Gehlert D.R.; Chronwall B.M.; Schafer M.P.; O'Donohue T.L. Localization of neuropeptide Y messenger ribonucleic acid in rat and mouse brain by in situ hybridization. Synapse 1987, 1, 25-31.
32. Morris B.J. Neuronal localisation of neuropeptide Y gene expression in rat brain. J. Comp. Neurol. 1989, 290, 358-68.
33. Adrian T.E.; Allen J.M.; Bloom S.R.; Ghatei M.A.; Rossor M.N.; Roberts G.W.; Crow T.J.; Tatemoto K., Polak J.M. Neuropeptide Y distribution in human brain. Nature 1983, 306, 584-586.
34. Chan-Palay V.; Allen Y.S.; Lang W.; Haesler U.; Polak J.M. Cytology and distribution in normal human cerebral cortex of neurons immunoreactive with antisera against neuropeptide Y. J. Comp. Neurol. 1985, 238, 382-389.
35. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 1996, 65, 165-174.
36. Hokfelt T.; Lundberg J.M.; Schultzberg M.; Johansson O.; Skirboll L.; Anggard A.; Fredholm B.; Hamberger B.; Pernow B.; Rehfeld J.; Goldstein M. Cellular localization of peptides in neural structures. Proc. R. Soc. Lond B. Biol. Sci. 1980, 210, 63-77.
37. Hokfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991, 7, 867-879.
38. Kelly R.B.; Grote E. Protein targeting in the neuron. Annu. Rev. Neurosci. 1993, 16, 95-127.
39. Ubink R.; Calza L.; Hokfelt T. 'Neuro'-peptides in glia: focus on NPY and galanin. Trends Neurosci. 2003, 26, 604-609.
40. Lundberg J.M.; Terenius L.; Hokfelt T.; Goldstein M. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci. Lett. 1983, 42, 167-172.
41. Kohler C.; Smialowska M.; Eriksson L.G.; Chanpalay V.; Davies S. Origin of the neuropeptide Y innervation of the rat retrohippocampal region. Neurosci. Lett. 1986, 65, 287-92.
42. Dumont Y.; Martel J.C.; Fournier A.; St-Pierre S.; Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 1992, 38, 125-67.
43. Holets V.R.; Hokfelt T.; Rokaeus A.; Terenius L.; Goldstein M. Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience 1998, 24, 893-906.
44. Hokfelt T.; Broberger C.; Zhang X.; Diez M.; Kopp J.; Xu Z.; Landry M.; Bao L.; Schalling M.; Koistinaho J.; DeArmond S.J.; Prusiner S. Gong J. Walsh J.H. Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res. Brain Res. Rev. 1998, 26, 154-166.
45. Redrobe J.P.; Dumont Y.; St-Pierre J.A.; Quirion R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 1999, 848, 154-166.
46. Blomqvist A.G.; Herzog H. Y-receptor subtypes-how many more? Trends Neurosci. 1997, 20, 294-298.
47. Michel M.C.; Beck-Sickinger A.; Cox H.; Doods H.N.; Herzog H.; Larhammar D.; Quirion R.; Schwartz T.; Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50, 143-150.
48. Hokfelt T.; Bartfai T.; Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol. 2003, 2, 463-472.
49. Lundell I.; Blomqvist A.G.; Berglund M.M.; Schober D.A.; Johnson D.; Statnick M.A.; Gadski R.A.; Gehlert D.R.; Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 1995, 270, 29123-29128.
50. Lundell I.; Statnick M.A.; Johnson D.; Schober D.A.; Starback P.; Gehlert D.R.; Larhammar D. The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptor. Proc. Natl. Acad. Sci. U S A. 1996, 93, 5111-5115.
51. Parker R.M.; Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J. Neurosci. 1999, 11, 1431-1449.
52. Gregor P;; Feng Y.; DeCarr L.B.; Cornfield L.J.; McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 1996, 271, 27776-27781.
53. Matsumoto M.; Nomura T.; Momose K.; Ikeda Y.; Kondou Y.; Akiho H.; Togami J.; Kimura Y.; Okada M.; Yamaguchi T. Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J. Biol. Chem. 1996, 271, 27217-27220.
54. Larson E.T.; Fredriksson R.; Johansson S.R.; Larhammar D. Cloning, pharmacology, and distribution of the neuropeptide Y-receptor Yb in rainbow trout. Peptides 2003, 24, 385-395.
55. Fredriksson R.; Larson E.T.; Yan Y.L.; Postlethwait J.H.; Larhammar D. Novel neuropeptide Y Y2-like receptor subtype in zebrafish and frogs supports early vertebrate chromosome duplications. J. Mol. Evol. 2004, 58, 106-114.
56. Bromee T.; Sjodin P.; Fredriksson R.; Boswell T.; Larsson T.A.; Salaneck E.; Zoorob R.; Mobell N.; Larhammar D. Neuropeptide Y-family receptors Y6 and Y7 in chicken. Cloning, pharmacological characterization, tissue distribution and conserved synteny with human chromosome region. FEBS J. 2006, 273, 2048-2063.
57. Jacques D.; Dumont Y.; Fournier A.; Quirion R. Characterization of neuropeptide Y receptor subtypes in the normal human brain, including the hypothalamus. Neuroscience 1997, 79, 129-148.
58. Dumont Y.; Jacques D.; Bouchard P.; Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 1998, 402, 372-384.
59. Kopp J.; Xu Z.Q.; Zhang X.; Pedrazzini T.; Herzog H.; Kresse A.; Wong H.; Walsh J.H.; Hokfelt T. Expression of the neuropeptide Y Y1 receptor in the CNS of rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience 2002, 111, 443-532.
60. Jacques D.; Tong Y.; Dumont Y.; Shen S.H.; Quirion R. Expression of the neuropeptide Y Y1 receptor mRNA in the human brain: an in situ hybridization study. Neuroreport 1996, 7, 1053-1056.
61. Caberlotto L.; Fuxe K.; Sedvall G.; Hurd Y.L. Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatum. Eur. J. Neurosci. 1997, 9, 1212-1225.
62. Wahlestedt C.; Yanaihara N.; Hakanson R. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept. 1986, 13, 307-318.
63. Pickel V.M.; Beck-Sickinger A.G.; Chan J.; Weiland H.A. Y1 receptors in the nucleus accumbens: ultrastructural localization and association with neuropeptide Y. J. Neurosci. Res. 1998, 52, 54-68.
64. Paredes M.F.; Greenwood J.; Baraban S.C. Neuropeptide Y modulates a G protein-coupled inwardly rectifying potassium current in the mouse hippocampus. Neurosci. Lett. 2003, 340, 9-12.
65. St-Pierre J.A.; Nouel D.; Dumont Y.; Baudet A.; Quirion R. Association of neuropeptide Y Y1 receptors with glutamate-positive and NPY-positive neurons in rat hippocampal cultures. Eur. J. Neurosci. 2000, 12, 1319-1330.
66. Caberlotto L.; Fuxe K.; Hurd Y.L. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J Chem. Neuroanat. 2000, 20, 327-337.
67. Gustafson E.L.; Smith K.E.; Durkin M.M.; Walker M.W.; Gerald C.; Weinshank R.; Branchek T.A. Distribution of the neuropeptide Y Y2 receptor mRNA in rat central nervous system. Brain Res. Mol. Brain Res. 1997, 46, 223-235.
68. Stanic D.; Brumovsky P.; Fetissov S.; Shuster S.; Herzog H.; Hokfelt T. Characterization of-neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J. Comp. Neurol. 2006, 499, 357-390.
69. Caberlotto L.; Fuxe K.; Rimland J.M.; Sedvall G.; Hurd Y.L. Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human postmortem brain. Neuroscience 1998, 86, 167-178.
70. Dumont Y.; Fournier A.; Quirion R. Expression and characterization of the neuropeptide Y Y-5 receptor subtype in the rat brain. J. Neurosci. 1998, 18, 5565-5574.
71. Nichol K.A.; Morey A.; Couzens M.H.; Shine J.; Herzog H.; Cunningham A.M. Conservation of expression of neuropeptide Y5 receptor between human and rat hypothalamus and limbic regions suggests an integral role in central neuroendocrine control. J. Neurosci. 199, 19, 10295-10304.
72. Jacques D, Tong Y.; Shen, S.H.; Quirion R. Discrete distribution of the neuropeptide Y Y5 receptor gene in the human brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 1998, 61, 100-107.
73. Grove K.P.; Campbell R.E.; Ffrench-Mullen J.M.; Cowley M.A.; Smith M.S. Neuropeptide Y Y5 receptor protein in the cortical/limbic system and brainstem of the rat expression on gamma-aminobutyric acid and corticotropin-releasing hormone neurons. Neuroscience 2000 100, 731-740.
74. Pitkanen A.; Beal M.F.; Sirvio J.; Swartz K.J.; Mannisto P.T.; Riekkinen P.J. Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats. Neuropeptides 1989, 14, 197-207.
75. Stenfors C.; Theodorsson E.; Mathe A.A. Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J. Neurosci. Res. 1989, 24, 445-450.
76. Marksteiner J.; Lassmann H.; Saria A.; Humpel C.; Meyer D.K.; Sperk G. Neuropeptide Levels after Pentylenetetrazol Kindling in the Rat. Eur. J. Neurosci. 1990, 2, 98-103.
77. Marksteiner J.; Ortler M.; Bellmann R.; Sperk G. Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci. Lett. 1990, 112, 143-148.
78. Marksteiner J.; Prommegger R.; Sperk G. Effect of anticonvulsant treatment on kainic acid-induced increases in peptide levels. Eur. J. Pharmacol. 1990, 181, 241-246.
79. Bendotti C.; Vezzani A.; Serafini R.; Servadio A.; Rivolta R.; Samanin R. Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: comparison with the expression of preprosomatostatin mRNA. Neurosci. Lett. 1991, 132, 175-178.
80. Sperk G.; Marksteiner J.; Gruber B.; Bellmann R.; Mahata M.; Ortler M. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience 1992, 50, 831-846.
81. Rizzi M.; Monno A.; Samanin R.; Sperk G.; Vezzani A. Electrical kindling of the hippocampus is associated with functional activation of neuropeptide Y-containing neurons. Eur. J. Neurosci. 1993, 5, 1534-1538.
82. Gruber B.; Greber S.; Rupp E.; Sperk G. Differential NPY mRNA expression in granule cells and interneurons of the rat dentate gyrus after kainic acid injection. Hippocampus 1994, 4, 474-482.
83. Schwarzer C.; Williamson J.M.; Lothman E.W.; Vezzani A.; Sperk G. Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience 1995, 69, 831-845.
84. Rosen J.B.; Kim S.Y.; Post R.M. Differential regional and time course increases in thyrotropin-releasing hormone, neuropeptide Y and enkephalin mRNAs following an amygdala kindled seizure. Brain Res. Mol. Brain Res. 1994, 27, 71-80.
85. McCarthy J.B.; Walker M.; Pierce J.; Camp P.; White J.D. Biosynthesis and metabolism of native and oxidized neuropeptide Y in the hippocampal mossy fiber system. J. Neurochem. 1998, 70, 1950-1963.
86. Tu B.; Timofeeva O.; Jiao Y.; Nadler J.V. Spontaneous release of neuropeptide Y tonically inhibits recurrent mossy fiber synaptic transmission in epileptic brain. J. Neurosci. 2005, 25, 1718-1729.
87. Furtinger S.; Pirker S.; Czech T.; Baumgartner C.; Ransmayr G.; Sperk G. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J. Neurosci. 2001, 21, 5804-5812.
88. Sloviter R.S. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the "dormant basket cell" hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus 1991, 1, 41-66.
89. de Lanerolle N.C.; Kim J.H.; Robbins R.J.; Spencer D.D. Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res. 1989, 495, 387-395.
90. Schwarzer C.; Kofler N.; Sperk G. Up-regulation of neuropeptide Y-Y2 receptors in an animal model of temporal lobe epilepsy. Mol. Pharmacol. 1998, 53, 6-13.
91. Gobbi M.; Gariboldi M.; Piwko C.; Hoyer D.; Sperk G.; Vezzani A. Distinct changes in peptide YY binding to, and mRNA levels of Y1 and Y2 receptors in the rat hippocampus associated with kindling epileptogenesis. J. Neurochem. 1998, 70, 1615-1622.
92. Gobbi M.; Monhemius R.; Samanin R.; Mennini T.; Vezzani A. Cellular localization of neuropeptide-Y receptors in the rat hippocampus: long-term effects of limbic seizures. Neuroreport 1996, 7, 1475-1480.
93. Kofler N.; Kirchmair E.; Schwarzer C.; Sperk G. Altered expression of NPY-Y1 receptors in kainic acid induced epilepsy in rats. Neurosci. Lett. 1997, 230, 129-132.
94. Kopp J.; Nanobashvili A.; Kokaia Z.; Lindvall O.; Hokfelt T. Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis. Brain. Res. Mol. Brain Res. 1999, 72, 17-29.
95. Vezzani A.; Moneta D.; Mule F.; Ravizza T.; Gobbi M.; French-Mullen J. Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures. Epilepsia 2000, 41 (Suppl 6), 115-121.
96. Vezzani A.; Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides 2004, 38, 245-252.
97. Erickson J.C.; Clegg K.E.; Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381, 415-421.
98. Baraban S.C.; Hollopeter G.; Erickson J.C.; Schwartzkroin P.A.; Palmiter R.D. Knock-out mice reveal a critieal antiepileptic role for neuropeptide Y. J. Neurosci. 1997, 17, 8927-8936.
99. Vezzani, A.; Michalkiewicz M.; Michalkiewicz T.; Moneta D.; Ravizza T.; Richichi C.; Aliprandi M.; Mule P.; Pirona L.; Gobbi M.; Schwarzer C.; Sperk G. Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience 2002, 110, 237-243.
100. Richichi C.; Lin E.J.; Stefanin D.; Colella D.; Ravizza T.; Grignaschi G.; Veglianese P.; Sperk G.; During M.J.; Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004, 24, 3051-3059.
101. 5 receptors. Eur. J. Neurosci. 2005, 22, 1417-1430.
102. Bijak M.; Smialowska M. Effects of neuropeptide Y on evoked potentials in the CA1 region and the dentate gyrus of the rat hippocampal slice. Pol. J. Pharmacol. 1995, 47, 333-338.
103. Smialowska M.; Bijak M.; Sopala M.; Tokarski K. Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological. study. Neuropeptides 1996, 30 7-12.
104. Klapstein G.J.; Colmers W.F. Neuropeptide Y suppresses epilepti-form activity in rat hippocampus in vitro. J. Neurophysiol. 1997, 78, 1651-1661.
105. Bijak M. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes. Neurosci. Lett. 1999, 268, 115-118.
106. Reibel S.; Nadi S.; Benmaamar R.; Larmet Y.; Carnahan J.; Marescaux C.; Depaulis A. Neuropeptide Y and epilepsy: varying effects according to seizure type and receptor activation. Peptides 2001, 22, 529-539.
107. Woldbye D.P.; Nanobashvili A.; Husum H.; Bolwig T.G.; Kokaia M. Neuropeptide Y inhibits in vitro epileptiform activity in the entorhinal cortex of mice. Neurosci. Lett. 2002, 333, 127-130.
108. Patrylo P.R.; van den Pol A.N.; Spencer D.D.; Williamson A. NPY inhibits glutamatergic excitation in the epileptic human dentate gyrus. J. Neurophysiol. 1999, 82, 478-483.
109. Woldbye D.P.; Madsen T.M.; Larsen P.J.; Mikkelsen J.D.; Bolwig T.G. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res. 1996, 737, 162-168.
110. Klenip K.; Woldbye D.P. Repeated inhibitory effects of NPY on hippocampal CA3 seizures and wet dog shakes. Peptides 2001, 22, 523-527.
111. Woldbye D.P.; Larsen PJ.; Mikkelsen J.D.; Klemp K.; Madsen T.M.; Bolwig T.G. Powerful inhibition of kainic acid seizures by neuroneptide Y via Y5-like receptors. Nat. Med. 1997, 3, 761-764.
112. Madsen T.M.; Woldbye D.P.; Bolwig T.G.; Mikkelsen J.D. Kainic acid seizure suppression by neuropeptide Y is not correlated to immediate early gene mRNA levels in rats. Neurosci. Lett. 1999, 271, 21-24
113. Mazarati A.; Wasterlain C.G. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci. Lett. 2002, 331, 123-127.
114. Reibel S.; Benmaamar R.; Le B.T.; Larmet Y.; Kalra S.P.; Marescaux C.; Depaulis A. Neuropeptide Y delays hippocampal kindling in the rat. Hippocampus 2003, 13, 557-560.
115. Woldbye D.P. Antiepileptic effects of NPY on pentylenetetrazole seizures. Regul. Pept. 1999, 75-76, 279-282.
116. Stroud L.M.; O'Brian T.J.; Jupp B,; Wallengren C.; Morris M.J. Neuropeptide Y suppresses absence seizures In a genetic rat model. Brain Res. 2005, 1033, 151-156.
117. Bard JA.; Walker M.W.; Branchek T.A.; Weinshank R.L. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 1995, 270, 26762-26765.
118. Gerald C.; Walker M.W.; Criscione L.; Gustafson E.L.; Batzl-Hartmann C.; Smith K.E.; Vaysse P.; Durkin M.M.; Laz T.M.; Linemeyer D.L.; Schaffhauser A.O.; Whitebread S.; Hofbauer K.G.; Taber R.I.; Branchek T.A.; Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171.
119. Gregor P.; Feng Y.; DeCarr L.B.; Cornfield L.J.; McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 1996, 271, 27776-27781.
120. Ho M.W.; Beck-Sickinger A.G.; Colmers W.F. Neuropeptide Y(5) receptors reduce synaptic excitation in proximal subiculum, but not epileptiform activity in rat hippocampal slices. J. Neurophysiol. 2000, 83, 723-734.
121. El Bahh B.; Cao J.Q.; Beck-Sickinger A.G.; Colmers W.F. Blockade of neuropeptide Y(2) receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246. Br. J. Pharmacol. 2002, 136, 502-509.
122. Lin E.J.; Young D.; Baer K.; Herzog H.; During M.J. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 2006, 47, 773-780.
123. Nanobashvili A.; Woldbye D.P.; Husum H.; Bolwig T.G.; Kokaia M. Neuropeptide Y Y5 receptors suppress in vitro spontaneous epileptiform bursting in the rat hippocampus. Neuroreport 2004, 15, 339-343.
124. Benmaamar R.; Richichi C.; Gobbi M.; Daniels A.J.; Beck-Sickinger A.G.; Vezzani A. Neuropeptide Y Y5 receptors inhibit kindling acquisition in rats. Regul. Pept. 2005, 125, 79-83.
125. Woldbye D.P.; Nanobashvili A.; Sorensen A.T.; Husum H.; Bolwig T.G.; Sorensen G.; Ernfors P.; Kokaia M. Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol. Dis. 2005, 20, 760-772.
126. Marsh D.J.; Baraban S.C.; Hollopeter G.; Palmiter R.D. Role of the Y5 neuropeptide Y receptor in limbic seizures. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 13518-13523.
127. Baraban S.C. Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors. Epilepsia 2002, 43, 9-13.
128. Brooks P.A.; Kelly J.S.; Allen J.M.; Smith D.A.; Stone T.W. Direct excitatory effects of neuropeptide Y (NPY) on rat hippocampal neurones in vitro. Brain Res. 1987, 408, 295-298.
129. Gariboldi M.; Conti M.; Cavaleri D.; Samanin R.; Vezzani A. Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. Eur. J. Neurosci. 1998, 10, 757-759.
130. Vezzani A.; Rizzi M.; Conti M.; Samanin R. Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors. J. Nutr. 2000, 130 (Suppl 4), 1046-1048.
131. Husum H.; Gruber S.H.; Bolwig T.G.; Mathe A.A. Extracellular levels of NPY in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive Y1 receptor blockade. Neuropeptides 2002, 36, 363-369.
132. Mollereau C.; Mazarguil H.; Marcus D.; Quelven I.; Kotani M.; Lannoy V.; Dumont Y.; Quirion R.; Detheux M.; Parmentier M.; Zajac J.M. Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists. Eur. J. Pharmacol. 2002, 451, 245-256.
133. Benmaamar R.; Pham-Le B.T.; Marescaux C.; Pedrazzini T.; Depaulis A. Induced down-regulation of neuropeptide Y-Y1 receptors delays initiation of kindling. Eur. J. Neurosci. 2003, 18, 768-774.
134. Colmers W.F.; Lukowiak K.; Pittman Q.J. Neuropeptide Y reduces orthodromically evoked population spike in rat hippocampal CA1 by a possibly presynaptic mechanism. Brain Res. 1985, 346, 404-408.
135. Colmers W.F.; Lukowiak K.; Pittman Q.J. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J. Physiol. 1997, 383, 285-299.
136. Klapstein G.J.; Colmers W.F. On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus 1993, 3, 103-111.
137. McQuiston A.R.; Colmers W.F. Neuropeptide Y2 receptors inhibit the frequency of spontaneous but not miniature EPSCs in CA3 pyramidal cells of rat hippocampus. J. Neurophysiol. 1996, 76, 3159-3168.
138. Bijak M. Neuropeptide Y reduces epileptiform discharge's and excitatory synaptic transmission in rat frontal cortex in vitro. Neuroscience 2000, 96, 487-494.
139. Greber S.; Schwarzer C.; Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 1994, 113, 737-740.
140. Silva A.P.; Carvalho A.P.; Carvalho C.M.; Malva J.O. Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyros. J. Neurochem. 2001, 79, 286-296.
141. Silva A.P.; Carvalho A.P.; Carvalho C.M.; Malva J.O. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 2003, 44, 282-292.
142. Rodi D.; Mazzuferi M.; Bregola G.; Dumont Y.; Fournier A.; Quirion R.; Simonato M. Changes in NPY-mediated modulation of hippocampal [3H]D-aspartate outflow in the kindling model of epilepsy. Synapse 2003, 49, 116-124.
143. Colmers W.F.; Klapstein G.J.; Fournier A.; St-Pierre S.; Treherne K.A. Presynaptic, inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by a Y2 receptor. Br. J. Pharmacol. 1991, 102, 41-44.
144. Qian J.; Colmers W.F.; Saggau P. Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J. Neurosci. 1997, 17, 8169-8117.
145. Weiser T.; Wieland H.A.; Doods H.N. Effects of the neuropeptide Y Y(2) receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in rat hippocampal slices. Eur. J. Pharmacol. 2000, 404, 133-136.
146. Guo H.; Castro P.A.; Palmiter R.D.; Baraban S.C. Y5 receptors mediate neuropeptide Y actions at excitatory synapses in area CA3 of the mouse hippocampus. J. Neurophysiol. 2002, 87, 558-566.
147. Wang S.J. Activation of neuropeptide Y Y1 receptors inhibits glutamate release through reduction of voltage-dependent Ca2+ entry in the rat cerebral cortex nerve terminals: suppression of this inhibitory effect by the protein kinase C-dependent facilitatory pathway. Neuroscience 2005, 134, 987-1000.
148. McQuiston A.R; Petrozzino J.J.; Connor J.A.; Colmers W.F. Neurapeptide Y1 receptors inhibit N-type calcium currents and reduce transient calcium increases in rat dentate granule cells. J. Neurosci. 1996, 16, 1422-1429.
149. Sun Q.Q.; Huguenard J.R.; Prince D.A. Neuropeptide Y receptors differentially modulate G-protein-activated inwardly rectifying K+ channels and high-voltage-activated Ca2+ channels in rat thalamic neurons. J. Physiol. 2001, 531, 67-79.
150. Sun Q.Q.; Akk G.; Huguenard J.R.; Prince D.A. Differential regulation of GABA release and neuronal excitability mediated by neuropeptide Y1 and Y2 receptors in rat thalamic neurons. J. Physiol. 2001, 531, 81-94.
151. Drumheller A.; Bouali S.M.; Fournier A.; St-Pierre S.; Jolicoeur F.B. Neurochemical effects of neuropeptide Y (NPY) and NPY2-36. Neuropeptides 1994, 27, 291-296.
152. Song C.; Earley B.; Leonard B.E. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression. Brain Behav. Immun. 1996, 10, 1-16.
153. Barone P.; Parashos S.A.; Palma V.; Marin G.; Campanella G.; Chase T.N. Dopamine D1 receptor modulation of pilocarpine-induced convulsions. Neuroscience 1990, 34, 209-217.
154. Barone P.; Palma V.; DeBartolomeis A.; Tedeschi E.; Muscettola G.; Campanella G. Dopamine D1 and D2 receptors mediate opposite functions in seizures induced by lithium-pilocarpine. Eur. J. Pharmacol. 1991, 195, 157-162.
155. Bo P.; Soragna D.; Marchioni E.; Candeloro, E.; Albergati A.; Savoldi F. Role of dopamine D-1 and D-2 antagonists in a model of focal epilepsy induced by electrical stimulation of hippocampus and amygdala in the rabbit Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19, 917-930.
156. Alam A.M.; Starr M.S. Dopaminergic modulation of pilocarpine-induced motor seizures in the rat: the role of hippocampal dopamine D1 receptors. Eur. J. Pharmacol. 1992, 222, 227-232.
157. Alam A.M.; Starr M.S. Dopaminergic modulation of pilocarpine-induced motor seizures in the rat: the role of hippocampal D2 receptors. Neuroscience 1993, 53, 425-431.
158. Clinckers R.; Smolders I.; Meurs A.; Ebinger G.; Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J. Neurochem. 2004, 89, 834-843.
159. Clinckers R.; Smolders I.; Meurs A.; Ebinger G.; Michotte Y. Anticonvulsant action of GBR-12909 and citaloprain against acute experimentally induced limbic seizures. Neuropharmacology 2004, 47, 1053-1061.
160. McNamara J.O.; Huang Y.Z.; Leonard A.S. Molecular signaling mechanisms underlying epileptogenesis. Sci. STKE. 2006, 2006, re12.
161. Sloviter R.S. On the role of seizure activity and endogenous excitatory amino acids in mediating seizurc-associated hippocampal damage. Adv. Exp. Med. Biol. 1986, 203, 659-671.
162. VanLardingham K.E.; Heinz E.R.; Cavazos J.E.; Lewis D.V. Magnetic resonance imaging evidence of hippocampal injury after prolonged focal febrile convulsions. Ann. Neurol. 1998, 43, 413-426.
163. Sloviter R.S. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia 1999, 40 (Suppl 1), 34-39.
164. Nadler J.V. The recurrent mossy fiber pathway of the epileptic brain. Neurochem. Res. 2003, 28, 1649-1658.
165. Silva A.P.; Pinheiro P.S.; Carvalho A.P.; Carvalho C.M.; Jakobsen B.; Zimmer J.; Malva J.O. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 2003, 17, 1118-1120.
166. Wu Y.F.; Li S.B. Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. Acta Pharmacol. Sin. 2005, 26, 63-68.
167. Chen S.H.; Cheung R.T. Peripheral and central administration of neuropeptide Y in a rat middle cerebral artery occlusion stroke model reduces cerebral blood flow and increases infarct volume. Brain Res. 2002, 927, 138-143.
168. Chen S.H.; Cheung R.T. Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats. Neuroscience 2003, 116, 119-126.
169. Cheung R.T.; Cechetto D.F. Neuropeptide Y-Y1 receptor antisense oligodeoxynucleotide increases the infarct volume after middle cerebral artery occlusion in rats. Neuroscience 2000, 98, 771-777.
170. Hansel D.E.; Eipper B.A.; Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001, 410, 940-944.
171. Howell O.W.; Scharfman H.E.; Herzog H.; Sundstrom L.E.; Beck-Sickinger A.; Gray W.P. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J. Neurochem. 2003, 86, 646-659.
172. Howell O.W.; Doyle K.; Goodman J.H.; Scharfman H.E.; Herzog H.; Pringle A.; Beck-Sickinger A.G.; Gray W.P. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J. Neurochem. 2005, 93, 560-570.
173. Parent J.M.; Yu T.W.; Leibowitz R.T.; Geschwind D.H.; Sloviter R.S.; Lowenstein D.H. Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J. Neurosci. 1997, 17, 3727-3738.
174. Gray W.P.; Sundstrom L.E. Kainic acid increases the proliferation of granule cell progenitors in the dentate gyrus of the adult rat. Brain Res. 1998, 790, 52-59.
175. Parent J.M.; Janumpalli S.; McNamara J.O.; Lowenstein D.H. Increased dentate granule cell neurogenesis following amygdala kindling in the adult rat, Neurosci. Lett. 1998, 247, 9-12.
176. Parent J.M. The role of seizure-induced neurogenesis in epileptogenesis and brain repair. Epilepsy Res. 2002, 50, 179-189.
177. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11, 61-95.
178. Hamman J.H.; Enslin G.M.; Kotze A.F. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005, 19, 165-177.
179. Baura G.D.; Foster D.M.; Porte D. Jr.; Kahn S.E.; Bergman R.N.; Cobelli C.; Schwartz M.W. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J. Clin. Invest. 1993, 92, 1824-1830.
180. Banks W.A.; Kastin A.J.; Huang W.; Jaspan J.B.; Maness L.M. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996, 17, 305-311.
181. Banks W.A.; Tschop M.; Robinson S.M.; Heiman M.L, Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J. Pharmacol. Exp. Ther. 2002, 302, 822-827.
182. Banks W.A.; Kastin A.J.; Jaspan J;B. Regional variation in transport of pancreatic polypeptide across the blood-brain barrier of mice. Pharmacol. Biochem. Behav. 1995, 51, 139-147.
183. Kastin A.J.; Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am. J. Physiol. 1999, 276, 479-482.
184. Nonaka N.; Shioda S.; Niehoff M.L.; Banks W.A. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J. Pharmacol. Exp. Ther. 2003, 306, 948-953.
185. Held K.; Antonijevic I.; Murck H.; Kuenzel H.; Steiger A. Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology 2006, 31, 100-107.
186. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 2004, 104, 29-45.
187. Egleton R.D.; Davis T.P. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx. 2005, 2, 44-53.
188. Pardridge W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 2006, 6, 494-500.
189. Illum L. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 2003, 87, 187-198.
190. Lacroix J.S.; Ricchetti A.P.; Morel D.; Mossimann B.; Waeber B.; Grouzmann E. Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects. Br. J. Pharmacol. 1996, 118, 2079-2084.
191. Fehm H.L.; Perras B.; Smolnik R.; Kern W.; Born J. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology? Eur. J. Pharmacol. 2000, 405, 43-54.
192. Chen S.C.; Eiting K.; Cui K.; Leonard A.K.; Morris D.; Li C.Y.; Farber K.; Sileno A.P.; Houston M.E. Jr.; Johnson P.H.; Quay S.C.; Costantino H.R. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J. Pharm. Sci. 2006, 95, 1364-1371.
193. Hesketh P.J.; Grunberg S.M.; Gralla R.J.; Warr D.G.; Roila F.; de Wit R.; Chawla S.P.; Carides A.D.; Ianus J.; Elmer M.E.; Evans J.K.; Beck K.; Reines S.; Horgan K.J.; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 2003, 21, 4112-4119.
194. Kramer M.S.; Winokur A.; Kelsey J.; Preskorn S.H.; Rothschild A.J.; Snavely D.; Ghosh K.; Ball W.A.; Reines S.A.; Munjack D.; Apter J.T.; Cunningham L.; Kling M.; Bari M.; Getson A.; Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29, 385-392.
195. Keller M.; Montgomery S.; Ball W.; Morrison M.; Snavely D.; Liu G.; Hargreaves R.; Hietala J.; Lines C.; Beebe K.; Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 2006, 59, 216-223.
196. Zobel A.W.; Nickel T.; Kunzel U.E.; Ackl N.; Sonntag A.; Ising M.; Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34, 171-181.
197. Olesen J.; Diener H.C.; Husstedt I.W.; Goadsby P.J.; Hall D. Meier U.; Pollentier S.; Lesko L.M.; BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 2004, 350, 1104-1110.
198. Erondu N.; Gantz I.; Musser B.; Suryawanshi S.; Mallick M.; Addy C.; Cote J.; Bray G.; Fujioka K.; Bays H.; Hollander F.; Sanabria-Bohorquez S.M.; Eng W.; Langstrom B.; Hargreaves R.J.; Burns H.D.; Kanatani A.; Fukami T.; MacNeil D.J.; Gottesdiener K.M.; Amatruda J.M.; Kaufman K.D.; Heymsfield S.B. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006, 4, 275-282.
199. Gullestad L.; Bjuro T.; Aaberge L.; Apelland T.; Skardal R.; Kjekshus E.; Nordlander M.; Ablad B.; Pernow J. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur. Heart J. 2003, 24, 1120-1127.
200. McLean L.R.; Buck S.H.; Krstenansky J.L. Examination of the role of the amphipathic alpha-helix in the interaction of neuropeptide Y and active cyclic analogues with cell membrane receptors and dimyristoylphosphatidylcholine. Biochemistry 1990, 29, 2016-2022.
201. Hwa J.J.; Witten M.B.; Williams P.; Ghibaudi L.; Gao J.; Salisbury B.G.; Mullins D.; Hamud F.; Strader C.D.; Parker E.M. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am. J. Physiol. 1999, 277, 1428-1434.
202. Balasubramaniam. A.; Tao Z.; Zhai W.; Stein M.; Sheriff S.; Chance W.T.; Fischer. J.E.; Eden P.E.; Taylor J.E.; Liu C.D.; McFadden D.W.; Voisin T.; Roze C.; Laburthe M. Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine. J. Med. Chem. 2000, 43, 3420-3427.
203. Balasubramaniam A. Neuropeptide Y (NPY) family of hormones: progress in the development of receptor selective agonists and antagonists. Curr. Pharm. Des. 2003, 9, 1165-1175.
204. Balasubramaniam A.; Sheriff S.; Johnson ME.; Prabbakaran M.; Huang Y.; Fischer J.E.; Chance W.T. [D-TRP32]neuropeptide Y: a competitive antagonist of NPY in rat hypothalamus. J. Med. Chem. 1994, 37, 811-815.
205. Gerald C.; Walker M.W.; Criscione L.; Gustafson E.L.; Batzl-Hartmann C.; Smith K.E.; Vaysse P.; Durkin M.M.; Laz T.M;; Linemeyer D.L.; Schaffhauser A.O.; Whitebread S.; Hofbauer K.G.; Taber R.I.; Branchek T.A.; Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171.
206. Cabrele C.; Langer M.; Bader R.; Wieland H.A.; Doods H.N.; Zerbe O.; Beck-Sickinger A.G. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J. Biol. Chem. 2000, 275, 36043-36048.
207. Balasubramaniam A.; Sheriff S.; Zhai W.; Chance W.T. Bis(31/31′) [ICys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides 2002, 23, 1485-1490.
208. Bonini J.A.; Jones K.A.; Adham N.; Forray C.; Artymyshyn R.; Durkin M.M.; Smith K.E.; Tamm J.A.; Boteju L.W.; Lakhlani P.P.; Raddatz R.; Yao W.J.; Ogozalek K.L.; Boyle N.; Kouranova E.V.; Quan Y.; Vaysse P.J.; Wetzel JM.; Branchek T.A.; Gerald C.; Borowsky B. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 2000, 275, 39324-39331.
209. Balasubramaniam A.; Dhawan V.C.; Mullins D.E.; Chance W.T.; Sheriff S.; Guzzi M.; Prabhakaran M.; Parker E.M. Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90). J. Med. Chem. 2001, 44, 1479-1482.
210. Serradeil-Le Gal C.; Valette G.; Rouby P.E.; Pellet A.; Oury-Donat F.; Brossard G.; Lespy L.; Marty E.; Neliat G.; de Cointet P.; Maffrand J.P.; Le Fur G. SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995, 362, 192-196.
211. Hipskind P.A.; Lobb K.L.; Nixon J.A.; Britton T.C.;, Bruns R.F.; Catlow J.; Dieckman-McGinty D.K.; Gackenheimer S.L.; Gitter B.D.; Iyengar S.; Schober D.A.; Simmons R.M.; Swanson S.; Zarrinmayeh H.; Zimmerman D.M.; Gehlert D.R. Rotent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem. 1997, 40, 3712-3714.
212. Kanatani A.; Kanno T.; Ishibara A.; Hata M.; Sakuraba A.; Tanaka T.; Tsuchiya Y.; Mase T.; Fukuroda T.; Fukami T.; Ihara M. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. 1999, 266, 88-91.
213. Kanatani A.; Hata, M.; Mashiko S.; Ishihara X.; Okamoto O.; Haga Y.; Ohe T.; Kanno T.; Murai N.; Ishii Y.; Fukuroda T.; Fukami T.; Ihara M. A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. 2001, 59, 501-505.
214. Hokfelt T.; Broberger C.; Xu ZQ.; Sergeyev V.; Ubink R.; Diez M. Neuropeptides - an overview. Neuropharmacology 2000, 39, 1337-1356.
215. During M.J.; Kaplitt M.G.; Stern M.B.; Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 2001, 12, 1589-1591.
216. Mentlein R. Dipeptidyi-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
217. Karl T.; Hoffmann T.; Pabst R.; von Horsten S. Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol. Biochem. Behav. 2003, 75, 869-879.
218. Stenfors C.; Hellman U.; Silberring J. Characterization of endogenous neuropeptide Y in rat hippocampus and its metabolism by nanospray mass spectrometry. J. Biol. Chem. 1997, 272, 5747-5751.
219. Aydin K.; Serdaroglu A.; Okuyaz C.; Bideci A.; Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child Neurol. 2005, 20, 848-851.
220. Brill J.; Lee M.; Zhao S.; Fernald R.D.; Huguenard J.R. Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J. Neurosci. 2006, 26, 6813-6822.
221. Husum H.; Van Kammen D.; Termeer E.; Bolwig G.; Mathe A. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003, 28, 1292-1299.
222. York D.A.; Singer L.; Thomas S.; Bray G.A. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000, 16, 967- 975.